Grant: Knowledge Translation Supplement
University of Calgary
$77,269.00
Disseminating a novel rescue therapy for severe asthma to a wider commercialization focused audience
EF 2011-12
Résumé
The proposed grant focuses on enhancing the uptake of the research results of an ongoing Alberta Innovates Health Solutions (AI-HS) ForeFront grant to a commercialization focused audience. The AI-HS ForeFront grant is focused on animal efficacy and toxicology data for a PFC/CO2 based rescue therapy for the treatment of asthma and other respiratory diseases, as well as developing a regulatory overview for taking the formulation to human clinical trials. The research team has incorporated a start-up company, SolAeroMed Inc., to further develop and commercialize the PFC/CO2 technology. The proposed knowledge translation activities will focus on mediums for dissemination of the research findings, targeted to the appropriate parties capable of financing and supporting clinical development of the PFC/CO2 technology as a life saving therapy for acute asthma. Specific audiences targeted for dissemination of the research findings will include private financing groups such as angel investors and venture capitalists, as well as potential development partners, such as pharmaceutical companies. The proposed medium is a professionally designed company website for SolAeroMed, highlighting the efficacy results obtained in the AI-HS ForeFront grant. Furthermore, the hiring of Dr. Joseph Tucker in the capacity of a knowledge broker is proposed. Dr. Tucker is an experienced biotech executive with extensive regulatory and fundraising expertise. Dr. Tucker will facilitate connections with potential investors, provide direction on clinical development paths, and enable linkages to appropriate expertise for regulatory and other specialized knowledge areas to further develop the PFC/CO2 formulation. Finally, travel costs to a number of medical start-up investor conferences and meetings are proposed, supporting the dissemination of the forefront grant research results to potential investors and development partners.
Programme
Knowledge Translation Supplement
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
236026
Name
Green Francis H
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Meetings, Planning and Dissemination Grant: End of Grant Knowledge Supplement
Projecttitle
Disseminating a novel rescue therapy for severe asthma to a wider commercialization focused audience
Programtype2
Miscellaneous Programs
Orgnameinp2
University of Calgary
Cihramount2
$77,269
Cihrequipment2
$0
Programname2
Knowledge Translation Supplement
Keyworddelim
Asthma; Carbon Dioxide; Commercialization Audience; Perfluorocarbon
Abstract
The proposed grant focuses on enhancing the uptake of the research results of an ongoing Alberta Innovates Health Solutions (AI-HS) ForeFront grant to a commercialization focused audience. The AI-HS ForeFront grant is focused on animal efficacy and toxicology data for a PFC/CO2 based rescue therapy for the treatment of asthma and other respiratory diseases, as well as developing a regulatory overview for taking the formulation to human clinical trials. The research team has incorporated a start-up company, SolAeroMed Inc., to further develop and commercialize the PFC/CO2 technology. The proposed knowledge translation activities will focus on mediums for dissemination of the research findings, targeted to the appropriate parties capable of financing and supporting clinical development of the PFC/CO2 technology as a life saving therapy for acute asthma. Specific audiences targeted for dissemination of the research findings will include private financing groups such as angel investors and venture capitalists, as well as potential development partners, such as pharmaceutical companies. The proposed medium is a professionally designed company website for SolAeroMed, highlighting the efficacy results obtained in the AI-HS ForeFront grant. Furthermore, the hiring of Dr. Joseph Tucker in the capacity of a knowledge broker is proposed. Dr. Tucker is an experienced biotech executive with extensive regulatory and fundraising expertise. Dr. Tucker will facilitate connections with potential investors, provide direction on clinical development paths, and enable linkages to appropriate expertise for regulatory and other specialized knowledge areas to further develop the PFC/CO2 formulation. Finally, travel costs to a number of medical start-up investor conferences and meetings are proposed, supporting the dissemination of the forefront grant research results to potential investors and development partners.
Competitiondate
201106
Approvedterm2
1 yr 0 mth
Pinamesdelim
Green, Francis H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $77,269~ $0~